Table 2.
Vaccination recommendations in inflammatory bowel disease patients (reprinted from [22] with permission from Elsevier)
| Professional society, country, year | ||||||
|---|---|---|---|---|---|---|
| ACIP, USA, 2010 | ECCO, Europe, 2014 | PHAC, Canada, 2014 | ATAGI, Australia, 2015 | HCSP, France, 2014 | STIKO, Germany, 2010 | |
| Vaccine | ||||||
| Live vaccines | ||||||
| BCG (Bacillus Calmette-Guérin) | Not recommended Contraindicated during IT |
|||||
| Measles, mumps, rubella | Recommended at least 6 weeks before starting IT | Recommended at least 3 weeks before starting IT | Not recommended Contraindicated during IT | Recommended at least 2 weeks before starting IT | ||
| Varicella zoster | Recommended at least 1–3 months before starting IT Contraindicated during IT |
Recommended at least 3 weeks before starting IT Contraindicated during IT |
Not recommended Contraindicated during IT | Recommended at least 2 weeks before starting IT Contraindicated during IT |
||
| Rotavirus | Not recommended Contraindicated during IT |
|||||
| Yellow fever | Not recommended Contraindicated during IT | |||||
| Inactivated vaccines | ||||||
| Tetanus-diphteria-acellular pertussis (Tdap)-polio | Administer vaccine if not given over the past 10 years or give Tdap if Td ≥2 years, with a booster dose every 10 years | Not recommended but possible during IT | Administer vaccine if not given over the past 10 years, with a booster dose every 10 years Possible during IT |
|||
| Haemophilus influenzae b | Not recommended but possible during IT | A single dose is recommended in patients with IT | ||||
| Hepatitis B | Recommended (3 doses at 1, 1–2 and 4–6 months; if no response 1 month after finishing last dose then revaccinate with double dose) Possible during IT | Recommended (double dose at 0, 1 and 2 months; if no response 1 month after finishing last dose then revaccinate with double dose) Possible during IT | Not recommended but possible during IT | |||
| Meningococcal vaccination | Not recommended but possible during IT | A single dose of Men ACWY is recommended in patients with IT | ||||
| Pneumococcal vaccination | Recommended (PCV13 and PPSV23 8 weeks later; re-vaccinate with a single dose of PPSV23 5 years after) Possible during IT |
Recommended (PCV13 and PPSV23 8 weeks later; second dose of PPSV23 5–10 years after, third dose at 65 years) Possible during IT |
Recommended (PCV13 and PPSV23 8 weeks later; re-vaccinate with a single dose of PPSV23 5 years after) Possible during IT |
Recommended (a single dose of PPSV23 with a second dose 5 years in case of IT) Possible during IT |
||
| Human papillomavirus | Recommended through age 26 years (3 doses 0, 2 and 6 months with HPV4) Possible during IT |
Not recommended but possible during IT | Recommended through age 18 years in patients with IT (3 doses 0, 2 and 6 months with HPV4) Possible during IT |
Not recommended but possible during IT | ||
| Influenza | Recommended (annual vaccine with the TIV) Possible during IT |
|||||
| Hepatitis A | Recommended (2 doses at 0 and 6–12 months or 0 and 12–18 months with a booster dose >10 years) Possible during IT |
Not recommended but possible during IT | ||||
ACIP, Advisory Committee on Immunisation Practices; ECCO, European Crohn’s and Colitis Organization; PHAC, Public Health Agency of Canada; ATAGI, Australian Technical Advisory Group on Immunisation; HCSP, Haut Conseil de la Santé Publique; STIKO, Vaccination Committee of the State of Saxony; IT, immunosuppressive therapy; MenACWY, quadrivalent meningococcal vaccination; PCV13, 13-quadrivalent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; HPV4, quadrivalent HPV vaccine; TIV, trivalent inactivated vaccine.